tradingkey.logo

Ekso Bionics Holdings Inc

EKSO
View Detailed Chart

4.420USD

+0.140+3.27%
Close 09/19, 16:00ETQuotes delayed by 15 min
11.51MMarket Cap
LossP/E TTM

Ekso Bionics Holdings Inc

4.420

+0.140+3.27%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.27%

5 Days

+15.40%

1 Month

+42.58%

6 Months

+884.41%

Year to Date

+624.59%

1 Year

+253.60%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
95 / 207
Overall Ranking
209 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
34.750
Target Price
+711.92%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 38.82% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 17.93M.
Undervalued
The company’s latest PE is -1.36, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 405.06K shares, increasing 7.74% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 11.96K shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.
Ticker SymbolEKSO
CompanyEkso Bionics Holdings Inc
CEOMr. Scott G. Davis
Websitehttps://eksobionics.com/
KeyAI